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Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators 
of reflux-induced cell signalling in esophageal cells
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Nitric oxide (NO) produced by inducible nitric oxide synthase 
(iNOS) has been implicated in both DNA damage induction and 
aberrant cell signalling in various tissue and cell backgrounds. We 
investigated here the role of iNOS and NO in DNA damage induc-
tion and nuclear factor-kappa B (NF-κB) signalling in esophageal 
cells in vitro. As esophageal adenocarcinoma develops in a back-
ground of Barrett’s esophagus secondary to reflux disease, it is 
possible that inflammatory mediators like NO may be important 
in esophageal cancer development. We show that reflux compo-
nents like stomach acid and bile acids [deoxycholic acid (DCA)] 
can induce iNOS gene and protein expression and produce NO 
generation in esophageal cells, using real-time PCR, western 
blotting and NO sensitive fluorescent probes, respectively. This 
up-regulation of iNOS expression was not dependent on NF-κB 
activity. DCA-induced DNA damage was independent of NF-κB 
and only partially dependent on iNOS and NO, as measured by the 
micronucleus assay. These same reflux constituents also activated 
the oncogenic transcription factor NF-κB, as measured by tran-
scription factor enzyme-linked immunosorbent assay and gene 
expression studies with NF-κB linked genes (e.g. interleukin-8). 
Importantly, we show here for the first time that basal levels of 
NF-κB activity (and possibly acid and DCA-induced NF-κB) 
are dependent on iNOS/NO and this may lead to a positive feed-
back loop whereby induced iNOS is upstream of NF-κB, hence 
prolonging and potentially amplifying this signalling, presum-
ably through NO activation of NF-κB. Furthermore, we confirm 
increased protein levels of iNOS in esophageal adenocarcinoma 
and, therefore, in neoplastic development in the esophagus.
Introduction
Barrett’s esophagus (BE), a metaplastic condition predisposing 
patients to esophageal adenocarcinoma (EA), is caused by chronic 
exposure to gastroesophageal reflux (GER). GER causes sustained 
exposure of the esophageal mucosa to noxious luminal agents such 
as acid and bile. These agents are believed to drive the metaplastic 
process whereby the squamous epithelium is replaced by a columnar 
epithelium resembling the small intestine. Patients acquiring BE pro-
gress to adenocarcinoma at a rate between 0.4% per year (1) and 1% 
per year (2). As survival rates for patients with EA are atrocious, a 
better understanding of the biology of BE and the molecular pathways 
driving neoplastic progression are urgently needed. It is hoped that a 
better molecular understanding of the disease will lead to therapeutic 
targets for drug development and molecular markers to help identify 
patients at risk of developing cancer at an early stage.
One molecule of particular interest in a context of BE is inducible 
nitric oxide synthase (iNOS). In contrast to endothelial nitric oxide 
synthase, or neuronal nitric oxide synthase (nNOS), iNOS is expressed 
only after cellular activation, i.e. it is not expressed constitutively. The 
iNOS protein is responsible for the production of cellular nitric oxide 
(NO) from the oxidation of l-arginine, with both iNOS and NO being 
implicated in a number of biological processes. In infectious diseases, 
human macrophages have been shown to express the iNOS protein, 
with the generated NO contributing to the killing of various microbes 
(3–5). Increased iNOS protein expression and NO level have been 
found in many chronic inflammatory and autoimmune diseases such 
as rheumatoid arthritis (6–7), multiple sclerosis (8), asthma (9) and 
type 1 diabetes (10,11). Hence, given that BE arises in a background 
of chronic inflammation, this link between iNOS/NO and inflamma-
tion further highlights a potential role for iNOS in BE.
An increased level of iNOS expression is also often seen in neo-
plastic tissue. This elevation has been observed in malignancies of the 
breast (12), lung (13), prostate (14) and colon (15). In the esophagus, 
increased iNOS mRNA has been found early in the neoplastic path-
way, at the BE stage (16). Interestingly, neoplastic progression in the 
esophagus in rats has been halted on administration of the selective 
iNOS inhibitor S,S-1,4-phenylene-bis(1,2-ethanediyl) bis-isothiourea 
(17), indicating the potential of iNOS as a therapeutic target. In fur-
ther support of this, thioproline (a nitrite scavenger) has also been 
shown to block duodenal reflux-driven EA in the rat (18).
One of the main routes by which NO and related reactive nitro-
gen species (e.g. peroxynitrite and nitrogen dioxide) promote car-
cinogenesis is by their ability to induce DNA damage via single- and 
double-stranded DNA breaks (19,20) and by increased levels of 
deamination (21). NO can also exacerbate this genotoxicity, by simul-
taneously inhibiting DNA repair enzyme activity through tyrosine and 
cysteine nitrosation (22–24). In terms of the transcriptional control of 
iNOS induction, nuclear factor-kappa B (NF-κB) has been heavily 
implicated, as multiple κB-binding sites are located in its promoter 
(25,26). As both NF-κB and iNOS are centrally involved in inflamma-
tory processes, their association might well be expected. Other tran-
scription factors have also been implicated in the regulation of this 
gene though, including AP-1 (27,28).
NO has also been shown to have the ability to be a potent cell 
signalling molecule. It has been shown that NO can induce NF-κB 
activation (29,30), with the mechanism of action postulated to be 
via tyrosine modification (31). In addition to this, NO has also been 
seen to activate the AP-1 transcription factor (32–34), which has been 
shown to be via ERK activation (31). Conversely, in some cell types 
it has been shown that NO can inhibit both iNOS expression (35) and 
NF-κB activity (34) representing a negative feedback system. Hence, 
cell context and choice of iNOS stimulant appear to be important 
determinants.
Several groups have published data implicating iNOS in neoplastic 
progression in BE. Wilson et al. (36) showed up-regulation of iNOS 
mRNA by real-time PCR in 76% of BE patients and in 80% of EA 
patients. This work has been recently confirmed by Vaninetti et  al. 
(37) who showed up-regulation of intracellular iNOS at the RNA 
level in BE and EA patient tissues, although to a lesser extent than 
Wilson et al. (48% and 63%, respectively). As for the source of this 
up-regulation of iNOS, there have been several reports that reflux 
components such as the bile acids DCA (38) and GCDCA (39) can 
induce NO, presumably through increased iNOS expression. Indeed, 
duodenal reflux has been shown to induce esophageal iNOS in 
experimental rat models (40). In 2009, Jolly et al. (41) published data 
showing that the bile acid DCA caused DNA damage to esophageal 
cells in vitro, through an iNOS and NF-κB-dependent manner. As 
NF-κB is known to be activated by bile acids (42) and is known to be 
Abbreviations: BE, Barrett’s esophagus; DAF-2 DA, diaminofluorescein-2 
diacetate; DCA, deoxycholic acid; EA, esophageal adenocarcinoma; ELISA, 
enzyme-linked immunosorbent assay; GER, gastroesophageal reflux; HBSS, 
Hanks balanced salt solution; IHC, immunohistochemistry; iNOS, inducible 
nitric oxide synthase; MN, micronucleus; NF-κB, nuclear factor-kappa B; NO, 
nitric oxide.
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increasingly activated during neoplastic progression in BE (43,44) it 
would make intuitive sense if it were shown to drive iNOS expression 
in BE. We have reported previously that iNOS inhibition blocks bile 
acid-driven interleukin-8 (IL-8) expression (45). As IL-8 is a known 
NF-κB target gene, this may reflect a NF-κB-mediated effect, but 
could also relate to other signalling pathways upstream of IL-8. 
Therefore, detailed knowledge of the biology of iNOS activation and 
its association with NF-κB, in the context of reflux exposure in the 
esophagus is lacking and hence this study aimed to address this.
The reported observation by Jolly et al. (41) inspired us to ask more 
specific questions surrounding iNOS and NO, in particular the poten-
tial for establishing a cyclical positive feedback system, as NO has 
been shown to itself activate NF-κB (46,47). As the iNOS gene has 
been shown in other cell models to be induced by NF-κB activation, 
it was therefore considered possible that NO could induce the tran-
scription of iNOS, through NF-κB activation, which would lead to 
the production of further NO. In theory, this positive feedback loop 
could amplify or prolong NF-κB activity in the esophagus after reflux 
exposure. Prolonging or amplifying intracellular signalling in this 
manner would be particularly pertinent in reflux-driven esophageal 
cancer, as exposures to reflux only occur in a pulsatile nature, each of 
short duration. Hence, prolonging the effect of each pulse may explain 
how these short exposures produce such a dramatic effect in terms of 
carcinogenesis in the esophagus.
We have assessed here the role of iNOS and NO in reflux-induced 
DNA damage and NF-κB activation in esophageal OE33 cells. We did 
not entirely confirm the data from Jolly et al. (2009), i.e. we did not 
observe reflux-induced DNA damage in an NF-κB-dependent manner, 
nor does our data support the role of NF-κB as the primary transcrip-
tion factor driving iNOS expression in response to reflux exposure. 
We do, however, show here that reflux components including the 
bile acid DCA (deoxycholic acid) and acid (pH 5)  can up-regulate 
the iNOS gene (43- and 12-fold). Furthermore, DCA led to intracel-
lular NO production in an iNOS-dependent manner. iNOS was also 
shown to be upstream of basal and reflux-induced NF-κB activity, 
therefore potentially setting up a positive feedback system which may 
amplify or prolong DCA-induced NF-κB activity. Finally, we confirm 
increased iNOS abundance in esophageal cancer tissues, reinforcing 
the role of iNOS/NO in EA development.
Materials and methods
Micronucleus study
Freshly obtained OE33 cells (ECACC, Salisbury, UK) were cultured over-
night in 25 cm2 flasks prior to treatment with DCA. The following day, cells 
were exposed to 100  µM and 200  µM DCA in dimethyl sulfoxide for 4 h 
in serum-free media. The DCA was subsequently washed off and the cells 
cultured in fresh media containing 2 µg/ml cytochalasin B (Sigma–Aldrich, 
Poole, UK) for a further 20 h to allow the cells to divide. As cytochalasin B 
blocks cytokinesis producing binucleated cells, it is clear which cells have 
divided since exposure to DCA. Micronucleated OE33 cells were scored only 
in binucleate cells, with a minimum of 2000 cells per dose included. Duplicate 
cultures were produced and so ~4000 cells were studied per dose. In order to 
assess the contribution of NF-κB and/or iNOS to DCA-induced genotoxicity, 
inhibitors to both [10 µM IkK VII (IKK) and 10 µM 1400W (iNOS), both 
Merck, dissolved in dimethyl sulfoxide] were added to the cells for 30 min 
prior to the addition of DCA, with washing between DCA and inhibitor expo-
sure. Parallel cultures exposed to the inhibitors alone or dimethyl sulfoxide 
(negative control) were established and scored concurrently. Lower doses of 
DCA (100 and 200 µM) were used in the MN assay compared with the later 
studies (300 µM) due to previously noted toxicity with 300 µM doses of DCA 
at the necessarily longer assay time required for the MN assay. Longer expo-
sure times (4 h) were used here as compared with the later assays (60 min) as 
4 h exposure is standard for the MN assay (OECD guideline 487).
Gene expression and NF-κB activation study
For gene expression studies, freshly obtained OE33 cells were seeded into 
six-well tissue culture plates at a density of 0.3 × 106 per well. After serum 
starvation (24 h), cells were treated for 60 min with (i) DCA (300 µM), or (ii) 
medium with a pH reduced to pH 5, or (iii) both. An untreated control was run 
concurrently. These studies were carried out in triplicate. For inhibitor studies, 
OE33 cells were seeded into six-well tissue culture plates at a density of 
0.3 × 106 per well. After serum starvation (24 h), those cells to be treated with 
an inhibitor were pre-incubated with either 10 µM IKK inhibitor VII (IKK, 
Merck) or 10 µM 1400W (iNOS, Merck) for 30 min in serum-free medium. 
Following this, wells were washed once with phosphate-buffered saline prior 
to treatment with acid or DCA, in combination with the appropriate inhibitor, 
for 60 min. Untreated wells and wells where no inhibitor was added served as 
negative and positive controls.
For the pulsed exposures, OE33 cells were seeded as above and in some 
cases treated with the iNOS inhibitor for 30 min prior to DCA or pH 5 exposure. 
Exposure to either DCA (300 µM) or acid (pH 5) alone, or together was carried 
out for either 5 or 30 min. After the treatment time, the cells were washed once 
with phosphate-buffered saline and then fresh serum-free medium was added 
for the rest of the experimental time (or ‘rest time’), which was either to a total 
of 60 or 120 min (DCA alone only). This meant cells were treated for (i) 5 min 
with 55 or 115 min rest time or (ii) 30 min with 30 min or 90 min rest time. 
Nuclear protein was subsequently extracted and nuclear NF-κB (p65) levels 
were assessed by enzyme-linked immunosorbent assay (ELISA) (see below).
Real-time PCR
Immediately following treatment, RNA was extracted from the cells and 
real-time PCR was performed to analyse expression of the IL-8 and iNOS 
genes (β-actin was used as a housekeeping gene). RNA extraction and 
real-time PCR details have been published previously (48,49). In brief, RNA 
was extracted using Qiagen reagents in conjunction with a Qiacube system 
(Qiagen, Crawley, UK). On-column DNA digestion was employed and cDNA 
synthesized using the Quantitect RT-PCR kit (Qiagen). Real-time PCR was 
performed using SYBR green (Bio-Rad, Hemel Hempstead, UK) with the 
standard curve method utilizing a diluted reference cDNA to generate a stand-
ard curve, off which the cDNA levels (starting quantity mean) were read for 
the unknown RNA samples. These were then normalized to the corresponding 
β-actin values. Primers for iNOS were as follows: forward: 5′-GCA GAA TGT 
GAC CAT CAT GG-3′; reverse: 5′-ACA ACC TTG GTG TTG AAG GC-3′ 
(50). For IL-8 the primers were as follows: forward: 5′-CAA TCC TAG TTT 
GAT ACT CCC-3′; reverse: 5′-AAT TAC TAA TAT TGA CTG TGG AG-3′. 
For β-actin the primers were as follows: forward: 5′-GAT GGC CAC GGC 
TGC TTC-3′; reverse: 5′-TGC CTC AGG GCA GCG GAA-3′.
Western blotting
Following treatment with DCA, protein was extracted from scraped OE33 
cells with 200 µl RIPA buffer (Sigma–Aldrich) for 5 min at 4°C. Lysates were 
centrifuged for 10 min at 10 000 × g. Total protein was quantified using the DC 
Protein Assay (Bio-Rad) according to the manufacturers instructions. Protein 
separation (5 µg, denatured at 95°C for 5 min) by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis was carried out using 4% stacking gels (pH 6.8) 
and resolving gels of 8%. Protein blotting was carried out using the Mini-Trans 
Blot Cell (Bio-Rad) and Immuno-blot polyvinylidene fluoride (PVDF) mem-
branes (Bio-Rad). Following blotting, membranes were rinsed with 1× tris-
buffered saline with 0.1% Tween 20 (TBS/T) and primary antibodies [B-actin, 
Cell Signalling (#4970S), 1:1000 dilution, in blocking buffer and iNOS, Cell 
Signalling, (#2977S), 1:750 dilution, in blocking buffer] were added overnight 
at 4°C with gentle agitation. Following the primary antibody incubation, mem-
branes were washed 4 × 5 min in TBS/T at room temperature with strong agita-
tion. Horseradish peroxidase (HRP)-conjugated secondary antibodies [abcam 
(ab97080) 1:1000 dilution in blocking buffer] were added for 1 h at room tem-
perature with gentle agitation. Following the secondary antibody incubation 
membranes were again washed 4 × 5 min in TBS/T at room temperature with 
strong agitation. Proteins were visualized by enhanced chemiluminescence 
using the Immun-Star™ HRP Chemiluminescent kit (Bio-Rad), according to 
the manufacturers instructions. Membranes were exposed using a ChemiDoc 
XRS gel documentation system (Bio-Rad).
NF-κB analysis
In the case of NF-κB analysis, cells were treated as above and nuclear NF-κB 
(p65) levels were assessed using a transcription factor ELISA kit based on 
binding of nuclear extracts to a plate-bound oligo containing the consensus 
κB-binding sequence (Active Motif, La Hulpe, Belgium). Nuclear extracts 
were obtained using the Active Motif kit following the manufacturers recom-
mendations. The p65 transcription factor kit was used to assess nuclear levels 
of active (i.e. DNA binding) p65 in nuclear extracts following the manufac-
turers recommendations. Previous data (data not shown) have demonstrated 
consistent activation of NF-κB by DCA and acid and the potency of the NF-κB 
inhibitor used here.
Intracellular nitric oxide level assessment
OE33 cells were seeded into a black bottomed 96-well tissue culture plate 
(Greiner, Stonehouse, UK), at a density of 5000 cells per well in RPMI 1640 
E.McAdam et al.
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tissue culture medium overnight, then transferred to serum-free medium for 
24 h. The cells were washed once with Hanks balanced salt solution (HBSS, 
Sigma) and following this, 50 µl of a 5 µM solution of diaminofluorescein-2 
diacetate (DAF-2 DA, Invitrogen, Renfrew, Scotland), diluted in HBSS with 
20mM HEPES and 5mM glucose was added to all cell containing wells. 
This was incubated at 37°C for 1 h to allow the chemical to penetrate into 
the cells and be hydrolyzed to DAF-2. After this time, the cells were washed 
twice with HBSS and then treated with DCA +/– the iNOS inhibitor 1400W 
(co-treatment, not pre-treatment). Cells treated for 5 min were washed once 
with HBSS after treatment, then incubated in HBSS plus HEPES and glu-
cose for the remainder of the experimental time. The plate was transferred to a 
POLARstar Omega plate reader (BMG Labtech) and the fluorescence intensity 
measured at an excitation wavelength of 485 nm and an emission wavelength 
of 520 nm, every 10 min for a total of 180 min.
Immunohistochemistry
Suitable histological samples of Barrett’s esophagus (with adjacent squa-
mous, and/or adenocarcinoma tissue) were identified in the pathology tissue 
archive of ABMU Health Board. Identification of suitable tissues was aided 
through the use of a dedicated informatics platform that was able to inter-
rogate the pathology database. This platform was designed and developed in 
conjunction with the Health Informatics Research Unit at Swansea Medical 
School. Ethical approval was obtained from the Dyfed Powys Local Research 
Ethics Committee prior to the start of the project and the R&D office at the 
Health Board also gave approval for the study. Tissue sections were stained 
with a Ventana automated immunostainer using an iNOS antibody (AbCam, 
Cambridge, UK) at 1:100 dilution. Scoring of the staining was undertaken by 
two independent members of the research team (GF and APG) using a H-score 
approach. Staining intensity was scored 0–3 with 0 equating to no staining 
and 1, 2 and 3 equating to low, moderate and strong staining. A distribution 
score of 0–3 was also employed with 0 equating to no staining, and 1, 2 and 3 
equating to staining in up to 33% of cells, up to 66% of cells or up to 100% of 
cells in each section. The intensity and distribution scores were multiplied to 
obtain the final H-score.
Statistical analysis
Fishers Exact test was used to assess differences in micronucleus frequency in 
cells exposed to reflux agents and inhibitors. For the real-time PCR data, the 
immunohistochemistry (IHC) data and the p65 nuclear ELISA data, unpaired, 
two-tailed t-tests were used on the triplicate datasets comparing each treatment 
with the concurrent untreated control.
Results
DCA-induced chromosome damage is not NF-kB dependent
To further explore the data published by Jolly et al. (41), showing that 
bile acids induced DNA damage in a NF-κB and iNOS-dependent 
manner, we performed micronucleus (MN) studies in OE33 cells 
exposed to DCA (100 and 200 µM) with and without inhibitors for 
NF-κB (IKK VII) and iNOS (1400W). We have established previ-
ously that DCA can induce chromosome damage as measured by the 
MN assay and that this DNA damage is blocked by pre-treatment with 
antioxidants (42,44). This previous study also showed that other bile 
acids, or acid alone did not induce chromosome damage, hence only 
the bile acid DCA was used here. Figure 1A shows the results of these 
experiments. OE33 cells were treated with DCA (100 or 200 µM) for 
4 h and the frequencies of micronuclei were subsequently quantified 
after 1 cell cycle (i.e. 4 + 20 h). Treatment with 100 µM DCA did 
not induce significantly increased levels of MN, whereas 200  µM 
DCA induced a 1.8-fold increase in MN frequency that was signifi-
cant using Fishers Exact test (P = 0.007). When cells were pre-treated 
with a potent NF-κB inhibitor (IKK VII), no effect on DCA-induced 
DNA damage (200 µM) was observed and a significant increase in 
MN was still observed (P = 0.024). When cells were pre-treated with 
an iNOS inhibitor (1400W), there was no significant reduction in 
MN compared with treatment with DCA alone (P = 0.16). However, 
the significant increase in MN frequency seen with DCA (and DCA 
+ NF-κB inhibitor) was lost when the iNOS inhibitor was included 
when compared with the untreated controls, suggesting a partial effect 
on the DNA damaging potential of DCA. There was no increased cel-
lular toxicity induced by these treatments as evidenced by the fact that 
the binucleate frequency remained at similar levels to the untreated 
controls.
iNOS mRNA and protein levels are up-regulated by reflux 
components
OE33 cells exposed to acid (pH 5) or DCA (300 µM) for 1 h showed 
strong up-regulation of iNOS mRNA by real-time PCR (Figure 1B). 
Slightly higher doses of DCA (300 µM) were used here relative to the 
DNA damage study above to compensate for shorter durations of expo-
sure (1 h). Acid up-regulated iNOS by 12-fold with DCA up-regulating 
iNOS even more so, by 43-fold, combined treatment (acidic DCA) 
up-regulated iNOS less so, by 16-fold. The combined treatment (acid 
+ DCA) resulted in some toxicity as evidenced by reduced MTS read-
ings 24 h post-exposure (data not shown) and in cells lifting off the 
tissue culture flask. The changes in iNOS mRNA level were significant 
(P = 6.8 × 10–6 for acid, P = 1.7 × 10–5 for DCA, P = 5.9 × 10–4 for com-
bined acid and DCA) when using the two-tailed t-test.
Interestingly and in support of the MN data above, the up-regulation 
of iNOS by DCA, acid or acidic DCA was not dependent on NF-κB, as 
the pre-treatment with a potent NF-kB inhibitor while reducing iNOS 
gene expression, did not do so significantly (P = 0.371, P = 0.803 and 
P = 0.660, respectively).
iNOS protein levels were measured in DCA-exposed OE33 cells by 
western blotting. The results of these experiments are shown in Figure 2. 
Treatment with 450 µM DCA, but not 300 µM DCA for up to 8 h led 
to increases in iNOS protein levels. This data confirms the mRNA data 
that DCA can up-regulate iNOS. The reason that 300 µM DCA did not 
(A)
(B)
Fig. 1. (A) Micronucleus (Mn) data examining chromosome breakage, 
showing percentage of Mn induction (line graph, right-hand scale) by DCA 
(4 h exposure + 20 h recovery). DCA at 100 µM was insufficient to show 
significant induction of Mn. However, 200 µM DCA showed significant 
induction of Mn (P = 0.007). This induction was not abrogated by an 
inhibitor of NF-κB (IKK VII), but a (non-significant) effect was noted with 
an iNOS inhibitor (1400W). Bars show percentage of binucleate frequency 
(left-hand scale), as a measure of cytotoxicity—none was apparent. 
*P < 0.05, statistically significant relative to the untreated control . Note that 
iNOS inhibition led to loss of MN induction by DCA, however reduction 
was not significant relative to DCA (200 µM) alone (P = 0.16).(B) Real-time 
PCR data for iNOS induction by acid (pH 5) and DCA (300µM), as well as 
combined acidic DCA. All three treatments significantly up-regulated iNOS 
mRNA levels. Inhibition of NF-κB (IKK VII) had no significant effect on the 
level of iNOS induction observed by any of the three treatments.
iNOS and NO are important mediators of reflux-induced cell signalling
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up-regulate iNOS protein levels (but did up-regulate mRNA levels) is 
probably related to the lack of sensitivity with western blotting.
Nitric oxide is induced by DCA exposure
To examine if iNOS mRNA induction led to functional iNOS pro-
tein activity, NO levels were measured after stimulation with DCA. 
OE33 cells exposed to DCA showed significant induction of NO, 
as measured by the NO sensitive DAF fluorescent probe (Figure 3). 
This induction of NO was dependent on iNOS and was blocked by 
co-incubation with an iNOS inhibitor (1400W, 10 µM). There was 
a significant increase in NO after 120 and 180 min (P = 0.022 and 
P  =  0.039, respectively), with iNOS inhibition significantly reduc-
ing this increase after 120 min (P = 0.003), but this decrease was not 
quite statistically significant after 180 min (P = 0.067). Pulsed DCA 
exposure (5 min) representative of physiological exposure scenarios 
also led to elevated NO synthesis (P  =  0.050 and 0.039 after 120 
and 180 min, respectively), which was also significantly reduced on 
addition of the iNOS inhibitor after 180 min (P = 0.005) (results not 
shown). Measurement of NO after acid treatment of cells was not 
included here as technical issues with the fluorescence (presumably 
due to acid interference with the probe) were observed.
iNOS is not upstream of NF-κB after continuous exposure to DCA
In order to explore the possibility of a positive feedback system 
involving iNOS and NF-κB, we assessed p65 nuclear localization 
and IL-8 gene expression (a well-known NF-κB target gene) after 
continuous exposure to acid (pH 5) or DCA (300 µM) for 60 min, either 
in the presence or absence of the iNOS inhibitor (Figure  4). In both 
exposure scenarios, IL-8 expression was induced in an iNOS-dependent 
manner, with significant abrogation of expression in the presence of 
1400W (P = 0.005 for DCA and P = 0.008 for acid). This confirmed our 
previous data (45). However, NF-κB activity induced by DCA was not 
affected by inhibition of iNOS (P = 0.50), suggesting that iNOS was not 
involved upstream of NF-κB in DCA-exposed cells. In the case of acid-
exposed cells, significant abrogation of NF-κB activity was seen in the 
presence of the iNOS inhibitor (~20% reduction, P = 0.02), hence iNOS 
may be partly involved in acid-induced NF-κB activation. Interestingly 
in both sets of experiments (acid and DCA), the iNOS inhibitor alone led 
to a significant reduction in basal NF-κB activity (P = 0.005 for DCA 
and P = 0.002 for acid) highlighting the role for iNOS and NO in basal 
NF-κB signalling. Indeed, the reduction in NF-κB activity when cells 
were exposed to acid plus the iNOS inhibitor may be a reflection of the 
reduced background levels observed without acid.
iNOS may be upstream of NF-κB after a pulsed exposure to DCA
We considered that continuous exposure to DCA and acid (above) could 
mask any positive feedback system by supplying a steady stream of 
primary RO(N)S that would swamp lesser amounts of de novo iNOS-
driven NO. Hence, in order to circumvent this possibility, we chose to 
perform pulsed exposures. In these cases, it was presumed that as the 
DCA is removed after 5 or 30 min and the NF-κB level measured some 
time later (60 or 120 min), that de novo NF-κB activity, secondary 
to iNOS activity would be more obvious. Figure  5A shows that 
pulsed DCA exposures of 5 and 30 min induce NF-κB activity when 
measured at 60 min (P = 0.006 and P = 0.003, respectively). Only a 
30-min pulse activated NF-κB at 120 min (P = 6.5 × 10–4; P = 0.09 for 
the 5-min exposure). Interestingly, pulsed acid exposure (pH 5) did 
not activate NF-κB at all. Therefore, only DCA was considered in the 
following cyclical experiments. Figure  5B shows that inhibition of 
iNOS can significantly abrogate DCA-induced NF-κB activity after 
a 5 min pulse (P = 0.007), whereas the reduction in NF-κB activity 
by the iNOS inhibitor at 30 and 60 min was non-significant. Basal 
levels of nuclear NF-κB were again significantly reduced by the iNOS 
inhibitor (P = 0.031). As above, it is possible that the reduced basal 
level of NF-κB activity with the iNOS inhibitor is responsible (or at 
least partly responsible) for the drop in NF-κB activity when cells 
were exposed to pulsed DCA plus the iNOS inhibitor. Nonetheless, 
this data suggests a signalling role for iNOS/NO in NF-κB activity 
(basal or induced).
Immunohistochemistry for iNOS
In order to confirm the role of iNOS in patients with BE and EA, we 
studied iNOS protein levels by IHC in 39 tissues of squamous esopha-
gus, BE and EA. Consistent with previous reports, we saw increased 
iNOS staining in the advanced histological grades (ADC). Figure 6 
shows the staining scores for iNOS relative to the histology of the tis-
sue. Here, a H-score approach was used with the intensity score (0–3) 
multiplied by a distribution score (0–3). As the tissue progressed 
from BE to adenocarcinoma, there was increased iNOS staining. This 
increase was significant using a two-tailed t-test (P = 0.034). Using 
intensity alone it was also obvious that iNOS expression was linked 
to histology. There were 2 out of 10 tissues with squamous histol-
ogy with an intensity score of 2 or 3. This figure was 5 out of 17 for 
Barrett’s tissues and 6 out of 12 for adenocarcinoma. Interestingly, 
iNOS staining was not different between squamous and Barrett’s tis-
sue, although it should be pointed out that here squamous tissue was 
adjacent to either Barrett’s or adenocarcinoma tissue and hence may 
have some inflammation associated with it. Figure 6 shows examples 
of iNOS staining emphasizing the link to histology.
Discussion
We show here the central role that iNOS can play in intracellular 
signalling in esophageal cells. Not only is iNOS up-regulated by 
common reflux constituents, leading to NO production, but this axis 
also has the potential to amplify NF-kB activation. We show that 
iNOS up-regulation is not controlled by NF-κB after initial exposure 
to acid or the bile acid DCA in OE33 cells, nor is DCA-induced 
DNA damage NF-κB dependent in these cells. However, basal 
Fig. 2. Western blot data for iNOS protein levels in OE33 cells after exposure to DCA (300 and 450µM) for 2–6 h. iNOS protein levels across the time series 
increase (at 450 not 300 µM), whereas the housekeeping protein chosen as loading control (B-actin) does not. Left-hand image shows example of western blot 
(450 µM) and right-hand graph shows average densitometry of four separate westerns confirming increased iNOS protein levels after DCA exposure (450 µM). 
Due to variation in iNOS protein levels, the increases were not significant relative to the control (P = 0.18 for 6 h versus 0 h, at 450 µM).
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levels of NF-κB are dependent on iNOS (and presumably NO) and 
inhibition of iNOS significantly reduces basal NF-κB activity. Also 
in continuous acid exposure and pulsatile exposure to DCA, we show 
that iNOS can be located upstream of NF-κB, hence confirming the 
potential positive feedback system amplifying and prolonging NF-κB 
activation. However, the reduction in basal levels of NF-κB activity 
may also contribute to the drop in induced NF-κB activity after acid 
or DCA exposure. We also confirm previous reports that iNOS is 
up-regulated in adenocarcinoma tissue, reinforcing the notion that 
iNOS modulation is a physiological response to reflux exposure in 
vivo. Previous studies have highlighted the role of luminal NO at the 
gastroesophageal junction (51,52). In these studies it has been elegantly 
shown that dietary nitrates, after conversion to nitrite by saliva, can 
generate NO at the gastroesophageal junction due to combination 
with stomach acid. Hence, this luminal NO has been proposed to 
contribute to carcinogenesis in the esophagus due to the ability of 
NO to mutate DNA directly or to react with other dietary compounds 
to create mutagenic species. Our data here suggests that the burden 
of nitrosative stress in the esophagus is even further increased due 
to intracellular (as well as luminal) generation. However, in terms 
of NO-induced signalling effects at the gastroesophageal junction, 
both luminal and intracellular generated RO(N)S may be involved in 
carcinogenesis. Another recent report linking NO to carcinogenesis 
in the esophagus, demonstrated the role that NO plays in regulating 
intracellular pH. Goldman et  al. (53) using intricate measures of 
intracellular pH, showed that bile acid and stomach acid-induced 
iNOS blocks activity of the sodium/hydrogen exchanger that can 
pump protons out of cells to maintain a neutral intracellular pH. By 
acidifying the intracellular environment, iNOS and NO also play an 
important role in acid-induced signalling, DNA damage, toxicity and 
neoplastic development.
Our data here showed that the DNA damage induced by DCA was 
not dependent on NF-κB, which somewhat contradicts the study by 
Jolly et al. (41). We only studied DCA in this series of experiments, 
because our previous data showed that only DCA and not the other com-
monly refluxed bile acids, nor acid alone, was chromosome damaging 
(42). The reason for the discrepancy between our data and that of Jolly 
et al. could be multifaceted. Not only did we use different cells in this 
(A)
(B)
Fig. 3. Nitric oxide levels were assessed in DCA (300 µM)-treated OE33 cells by inclusion of a NO sensitive fluorescent probe (DAF-FM, Invitrogen). 
Fluorescence was measured in real-time with a plate reader. (A) Time series data graph (untreated, DCA treated and DCA + iNOS inhibitor treated). DCA 
induces elevated NO, and inhibition of iNOS prevented this. (B) Graph shows data for 60, 120 and 180 min only. *P < 0.05, **P < 0.01, respectively.
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study (OE33 versus Het1A), but we also used different DNA damage 
endpoints (micronucleus assay versus comet assay). Furthermore, dif-
ferent inhibitors of NF-κB were used by us (IKK VII) and by Jolly et al. 
(TPCK protease inhibitor). In our opinion the main difference to note 
is the latter, i.e the NF-κB inhibitor. We have extensive experience of 
studying NF-κB induction by oxidative stress and using direct measures 
of NF-κB activity, we are confident that the IKK VII inhibitor abolishes 
NF-κB activity specifically. The TPCK inhibitor is a non-specific inhibi-
tor of proteases, which are important in preventing IkB degradation, 
but will also have multiple off-target effects. Hence, the difference in 
the results between the two studies is possibly due to specific versus 
non-specific NF-κB effects. Our iNOS expression data supports our 
DNA damage data in that neither DCA induced up-regulation of iNOS 
nor DCA-induced DNA damage appears to be NF-κB dependent. Our 
iNOS western data shows increased iNOS protein production at higher 
doses of DCA (450 µM) than those showing increased gene expression, 
which presumably reflects the lesser sensitivity of western blotting com-
pared with real-time PCR.
The DNA damage induced by DCA, although not NF-κB dependent 
showed a possible association with iNOS and hence NO. However, the 
iNOS inhibitor did not significantly reduce the level of DCA-induced 
MN when compared with cells treated with DCA alone. If we accept 
that iNOS and NO were involved in some way in DCA-driven DNA 
damage then this would fit with the data from Jolly et al., who also 
showed that DCA-induced DNA damage was iNOS dependent 
(even though different iNOS inhibitors were used in the two studies; 
L-NAME and 1400W). This observation is certainly interesting and 
suggests that NO may be a key mediator of reflux-induced mutagen-
esis. It is well known that NO is a mutagen (20,54). Furthermore, 
NO is known to repress some DNA repair enzymes through tyrosine 
nitrosation (22,23), leaving cells susceptible to the mutagenic effects 
of nitrosative stress. Hence, the DNA damage induced in the cells 
here may have been the result of a two-pronged attack on both DNA 
and specific DNA repair proteins. It is also interesting to note that the 
induction of DNA damage by NO can be countered through an evolved 
pathway involving p53-mediated down-regulation of iNOS (55) fol-
lowing DNA damage induction. Hence, it is important to consider the 
antagonistic effects of iNOS stimulation by RONS and repression by 
DNA damage induced p53 activity. It is interesting to speculate that 
because mutations of the p53 gene are common in esophageal cancer 
development (56,57) the antagonistic balance in these cells could be 
altered. Clearly in esophageal tissues devoid of functional p53 pro-
teins, nitrosative stress may prevail with minimal repression of iNOS 
occurring. Our IHC data here [and previous reports by Wilson et al. 
(36) and Vaninetti et al. (37)] clearly showed up-regulation of iNOS 
in EA, hence casting doubt on the ability of p53 in these tissues to 
negatively regulate iNOS expression. It is important to note that p53 
and all other proteins can also be inactivated by nitrosative stress (58). 
In this context it is worth mentioning that in a previous study of EA 
tissues, there was a noted association between peroxynitrite staining 
(a result of NO and superoxide combination) and the presence of p53 
mutations (37) further emphasizing the possibility that p53 negatively 
regulates nitrosative stress.
Our IHC data showed significant increases in iNOS protein 
staining in adenocarcinomas relative to both BE tissue and 
squamous tissue. However, we saw no difference between BE 
and squamous with regards to iNOS protein levels. Both Wilson 
et  al. (36) and Vaninetti et  al. (37) have reported previously a 
large induction of iNOS mRNA levels in BE tissues relative to 
gastric tissue and squamous tissue, respectively. Interestingly, 
GERD (squamous) tissue was noted to show iNOS induction also 
(37). Although the discrepancy between our IHC data and the 
previous mRNA data may be due to RNA not always necessarily 
being translated into protein, there is also another explanation. 
This may centre on our squamous tissue being sourced from 
adjacent material to BE and adenocarcinoma tissue. Hence, this 
material may have artificially higher levels of iNOS due to the 
concurrent reflux exposure in this squamous material. Indeed, 
Wilson et al. (36) who also carried out some IHC in parallel to 
mRNA analysis noted higher iNOS protein staining in squamous 
tissues adjacent to BE tissue. Nonetheless, the three reports 
all confirm up-regulation of iNOS mRNA and or protein in 
neoplastic development in BE.
Our data clearly shows that under certain circumstances, iNOS 
sits upstream of NF-κB, suggesting that NO can induce NF-κB 
activity (e.g. the basal NF-κB data). Hence, reflux-induced oxidative/
nitrosative stress that activates NF-κB may be supplemented by 
secondary iNOS-induced NO production that is initially largely 
NF-κB independent. Interestingly, our real-time data on iNOS 
expression suggests non-significant reductions in iNOS expression 
when the NF-κB inhibitor is present in both continuous exposures to 
DCA and acid. Another interesting observation was that pulsed DCA, 
but not pulsed acid-induced NF-κB activity, therefore suggesting that 
the different reflux components may have differing NF-κB signalling 
potential. Bile acids like DCA may be more potent at inducing 
these effects due to better uptake into cells, through detergent-based 
mechanisms and active transport (59) coupled to membrane damage. 
Acid exposures may be buffered extra- and intracellularly and internal 
pH balanced by membrane pumps, leading to less acute effects. 
This is important in relation to which patients are at most risk of 
Fig. 4. NF-κB activity and IL8 mRNA levels are shown after continuous treatment with DCA (left hand graph) and acid (right hand graph) for 60 min. NF-κB is 
activated by DCA and acid. The iNOS inhibitor alone suppresses basal NF-κB activity in both cases and in combination with acid (but not DCA). IL-8 expression 
is also induced by DCA and acid and its induction is blocked by the iNOS inhibitor. *P < 0.05, ** P < 0.01.
E.McAdam et al.
2040
 at U
niversity of W
ales, Sw
ansea on O
ctober 29, 2012
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
esophageal cancer formation and offers the possibility that this may 
be determined by their relative reflux constituents.
In conclusion, we show here that iNOS and NO can be upstream 
of basal NF-κB activity in OE33 cells and could theoretically play a 
role in the known NF-κB activity that is linked to esophageal cancer 
development in vivo. As NO is also known to lead to DNA damage 
and inactivate negative regulators of carcinogenesis (e.g. DNA repair 
and p53 proteins), new therapies aimed at suppressing excess iNOS/
NO levels might represent effective treatment strategies for esopha-
geal (and other) cancers.
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